Company: PIII
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015305
Chunk: 226

Company: P3 Health Partners Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 226
---
 focused on healthcare services, technology and healthcare real estateGreg Kazarian62DirectorOperating Partner of Chicago Pacific Founders, a private equity fund focused on healthcare services, technology and healthcare real estateThomas E. Price, M.D.70DirectorDirector of: Triumph Orthopedics, LLC; HealthWiseFirst, LLC; Association Health Plans of America, LLC; Transformation Care Network; Botanicals Sciences, LLC; and Capital Ministries (non-profit)Jeffrey G. Park53DirectorPresident of Waltz Health, a digital health company

The remaining information required by this item will be included in our definitive Proxy Statement for the 2025 Annual Meeting of Stockholders and such information is incorporated herein by reference.

Item 11. Executive Compensation.

The information required by this item will be included in our definitive Proxy Statement for the 2025 Annual Meeting of Stockholders and such information is incorporated herein by reference.

P3 Health Partners Inc. | 2024 Form 10-K | 124

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Securities Authorized for Issuance Under Equity Compensation Plans (as of December 31, 2024)

Plan category:    Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and RightsWeighted Average Exercise Price of Outstanding Options, Warrants, and Rights (3)    Number of Securities Available for Future Issuance Under Equity Compensation Plans (excludes securities reflected in first column) (4)Equity compensation plans approved by security holders (1)7,416,743$2.646,996,501Equity compensation plans not approved by security holders (2)12,100,000$0.73—Total19,516,7436,996,501

_____________________________________________

(1)Consists of the 2021 Plan.

(2)Consists of the P3 Health Partners Inc. 2024 Employment Inducement Incentive Award Plan (the “2024 Plan”).

(3)The weighted average exercise price does not include restricted stock units granted under each of the 2021 Plan and the 2024 Plan.

(4)The number of shares of common stock reserved for issuance under the 2021 Plan will increase on the first day of each calendar year from January 1, 2022 and ending on and including January 1, 2031, by a number equal to the lesser of (i